Phio Pharmaceuticals Corp (PHIO): Kapitalisasi marang pendapatan
Phio Pharmaceuticals (PHIO) retains a dedicated team of scientists through long-term options, which stabilizes the development of oncology drugs. Competent management effectively protects the intellectual property of the INTASYL platform. Analyzing the P/S market multiple in GURU.Markets, we note that the mark serves as a current business valuation metric. Fundamental patents for carrier-free gene silencing create significant barriers to entry for new players in the sector.
Phio Pharmaceuticals (PHIO) - rincian metrik lan laporan keuangan
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Phio Pharmaceuticals|PHIO - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal phiopharma.com|PHIO - Gunggung utang perusahaan|Utang marang modal buku RXi Pharmaceuticals|PHIO - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Phio Pharmaceuticals|Indikator likuiditas cepet phiopharma.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
PHIO - Bathi resik|Proyeksi bathi mangsa ngarep Phio Pharmaceuticals|PHIO - Rasio rega marang bathi|Rega marang bathi mangsa ngarep phiopharma.com|PHIO - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan RXi Pharmaceuticals|PHIO - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan Phio Pharmaceuticals|PHIO - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan phiopharma.com|PHIO - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Phio Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:Phio Pharmaceuticals Corp
An analysis of the credit quality of Phio Pharmaceuticals (PHIO) requires an assessment of market value relative to generated cash flows. Business resilience is supported by inelastic demand for the unique self-delivering RNA strands of the INTASYL platform. This price-to-sales valuation measures the deviation of the current multiple from the statistical norm via standard deviations. An indicator move beyond two sigma boundaries signals potential returns but warns of the risk of a sharp correction.
Perusahaan pesaing
TEM (Tempus AI) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Qiagen QGEN|IONS - Kapitalisasi marang pendapatan|Repligen Corp. - Multiplikator P/S|RNA - Multiplikator P/S|CRSP: Multiplikator P/S|Kapitalisasi marang pendapatan genedx.com|RARE (Ultragenyx) - Multiplikator P/S|Rega marang dodolan Beam Therapeutics Inc BEAM|Kapitalisasi marang pendapatan SRPT (Sarepta Therapeutics Inc)|Multiplikator P/S Twist Bioscience Corp (TWST)|10x Genomics, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan NTLA (intelliatx.com)|Stoke Therapeutics, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan BioLife Solutions Inc BLFS|WVE: Multiplikator P/S|Kapitalisasi marang pendapatan Maze Therapeutics Corp|SION (Sionna Therapeutics Inc) - Multiplikator P/S|Multiplikator P/S primemedicine.com|Rasio rega marang pendapatan Taysha Gene Therapies, Inc. (TSHA)|Rasio rega marang pendapatan QURE (uniQure NV)|Rasio rega marang pendapatan MeiraGTx PLC MGTX|Koefisien rega marang pendapatan REGENXBIO Corp (RGNX)|SLDB - Rasio rega marang pendapatan|Rasio rega marang dodolan OCGN|PACB: Multiplikator P/S|Benitec Biopharma Inc - Rasio kapitalisasi pasar marang pendapatan|DSGN (Design Pharma) - Multiplikator P/S|Rocket Corp (RCKT) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan 4D Molecular Therapeutics (FDMT)|LXEO - Rega marang dodolan|Multiplikator P/S KRRO (Korro Bio)|EDIT: Rasio kapitalisasi marang pendapatan|SLN - Rasio rega marang pendapatan|PRQR (ProQR Therapeutics N.V.) - Rasio kapitalisasi marang pendapatan|CDXS: Multiplikator P/S|sangamo.com (SGMO) - Multiplikator P/S|Rasio rega marang pendapatan Nautilus Biotechnology, Inc.|Metagenomi Inc. - Rasio rega marang dodolan|Multiplikator P/S DTIL|GBIO (generationbio.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BOLD (Boundless Bio, Inc.)|Koefisien rega marang pendapatan Exicure Inc. (XCUR)|IMNN - Rasio rega marang pendapatan|Rega marang dodolan Mustang Bio, Inc.|RNAZ (transcodetherapeutics.com) - Kapitalisasi marang pendapatan|Bionano Genomics - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Applied DNA Sciences|bluebirdbio.com - Rasio rega marang dodolan|Multiplikator P/S IPA|OMGA (Omega Therapeutics Inc) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S OMIC (Singular Genomics Systems Inc)|Multiplikator P/S Regulus RGLS|SYRS - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan TBIO (telesisbio.com)|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Unity Biotechnology Inc.
